{"doi":"10.1016/j.ogla.2024.11.004","title":"Enhancing Detection of Glaucoma Progression","abstract":"PURPOSE: To test the hypothesis that a summary index derived from the central 12 points of the 24-2 visual field (12-point mean deviation [MD12]) could provide complementary information to that provided by the 24-2 visual field (VF) mean deviation (24-2 MD). DESIGN: Longitudinal observational study. PARTICIPANTS: One hundred twenty-five eyes (125 patients) with central damage or moderate to severe glaucoma from the Advanced Glaucoma Progression Study with ≥ 4 pairs of 10-2 and 24-2 Swedish Interactive Thresholding Algorithm standard VFs. METHODS: Baseline 10-2 and 24-2 VF dates were within 6 months, and the remaining pairs of VF tests were done in the same session. The MD12 index was calculated by averaging total deviation values from the central 12 points of 24-2 VF. Simple linear regression of MD against time was used to estimate 24-2 MD, 10-2 MD, and MD12 rates of change (RoC). Progression at the final follow-up visit was defined as a RoC < 0 dB/year with P < 0.05 for any summary index with confirmation. MAIN OUTCOME MEASURES: Proportion of progressing eyes based on 24-2 MD, 10-2 MD, and MD12 RoC. RESULTS: The average (standard deviation) baseline 24-2 and 10-2 MD were -9.0 ± 6.2 and -8.5 ± 5.4 dB, respectively. The mean follow-up time was 5.7 (±1.6) years. The three summary indices were highly correlated at baseline: r = 0.62 (95% confidence interval: 0.52-0.74) between 10-2 MD and 24-2 MD, 0.84 (95% confidence interval: 0.78-0.90) between MD12 and 24-2 MD, and 0.86 (95% confidence interval: 0.80-0.92) between 10-2 MD and MD12. The corresponding correlations between RoC were weaker: r = 0.41 (95% confidence interval: 0.37-0.45), 0.80 (95% confidence interval: 0.78-0.82), and 0.49 (95% confidence interval: 0.45-0.53). Glaucoma progression was detected in 29 (23.2%), 22 (17.6%), and 23 eyes (18.4%) based on the 24-2, 10-2, and MD12 RoC, respectively; 7 eyes (9.6%) exhibited progression based on MD12 RoC and not with 24-2 MD; only 3 of these eyes progressed according to 10-2. CONCLUSIONS: MD12 RoC and detection rates have a low level of agreement with those of 10-2 and hence do not replace the need for 10-2 VF MD to monitor central damage. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.","journal":"Ophthalmology Glaucoma","year":2024,"id":458763,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.6452,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1074668,"name":"Sajad Besharati","orcid":"0000-0002-6520-0877","position":1,"is_corresponding":false},{"id":316297,"name":"Vahid Mohammadzadeh","orcid":null,"position":2,"is_corresponding":false},{"id":1285051,"name":"Jane Zou","orcid":"0009-0001-3887-6097","position":3,"is_corresponding":false},{"id":1285566,"name":"Judy Figueroa","orcid":null,"position":4,"is_corresponding":false},{"id":920859,"name":"Massood Mohammadi","orcid":"0000-0002-3017-6643","position":5,"is_corresponding":false},{"id":315555,"name":"Kouros Nouri‐Mahdavi","orcid":"0000-0001-9403-8904","position":6,"is_corresponding":false},{"id":1086452,"name":"Maryam Ashrafkhorasani","orcid":"0000-0003-2046-5633","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-19T02:03:50.608887Z","pmid":"39542212","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}